We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    nanocovax | Covid19 | Vietnam
Previous Study | Return to List | Next Study

Study to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04922788
Recruitment Status : Active, not recruiting
First Posted : June 11, 2021
Last Update Posted : November 4, 2022
Sponsor:
Information provided by (Responsible Party):
Nanogen Pharmaceutical Biotechnology Joint Stock Company

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to evaluate the safety, immunogenicity, and efficacy of Nanocovax vaccine in volunteer subjects 18 years of age and older.

Condition or disease Intervention/treatment Phase
SARS-CoV-2 Infection COVID-19 Biological: Nanocovax Biological: Placebo Phase 3

Detailed Description:

This is a phase 3, adaptive, multicenter, randomized, double-blind, placebo control study to evaluate the safety, immunogenicity, and efficacy of the Nanocovax vaccine against COVID-19 in volunteer subjects 18 years of age and older.

Age stratified as 18-45, 45-60, and > 60 years of age.

The assessment of immunogenicity will be further expanded in a subset of Phase 3 (1000 participants).

Randomly assigned to vaccine or placebo group with a ratio of 2:1 (2 subjects injected with Nanocovax 25 mcg : 1 subject injected with placebo).

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 13000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: a Phase 3, Adaptive, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Immunogenicity, and Efficacy of the Nanocovax Vaccine Against COVID-19 in Volunteer Subjects 18 Years of Age and Older.
Actual Study Start Date : June 7, 2021
Estimated Primary Completion Date : December 7, 2022
Estimated Study Completion Date : December 7, 2022

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: 25 mcg Dose
Intramuscular injection, two doses given 28 days apart
 Biological: Nanocovax
Recombinant Protein spike (s) SARS-CoV-2 and 0,5 mg Aluminum adjuvant
Placebo Comparator: Placebo
Intramuscular injection, two doses given 28 days apart
 Biological: Placebo
0,5 mg Aluminum adjuvant


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Number of participants who experience a first episode of virologically-confirmed {reverse transcription polymerase chain reaction (RT-PCR) positive} case of COVID-19 of any severity [ Time Frame: From 14 days after the second dose of study intervention to the end of the study, up to 1 year ]
    Per 1000 person-years of follow-up

  2. Percentage of participants reporting Serious adverse events or medically attended adverse events [ Time Frame: From dose 1 through one year after the last dose ]
  3. Geometric mean of Anti-S IgG concentrations at each time point in a subset of participants [ Time Frame: days 0, 42, 180, 365 after vaccination ]
  4. Geometric mean of SARS-CoV-2 serum neutralizing titers by Plaque reduction neutralization test (PRNT) at each time point in a subset of participants [ Time Frame: days 0, 42 after vaccination ]

Secondary Outcome Measures :
  1. Percentage of participants reporting solicited local and systemic reactions [ Time Frame: 7 days after each study vaccination ]
  2. Percentage of participants reporting unsolicited vaccine-related ≥ Grade 2 adverse events [ Time Frame: 28 days after each study vaccination ]
  3. Proportion of participants achieving ≥4-fold rise of Anti-S IgG at each time point in a subset of participants [ Time Frame: days 0,42, 180, 365 after vaccination ]
  4. T-cell responses (intracellular cytokine staining) [ Time Frame: days 0, 42 after vaccination ]
    Change from baseline in the cell-mediated immune response in a subset of participants

  5. Number of participants who experience a first episode of virologically-confirmed {reverse transcription polymerase chain reaction (RT-PCR) positive} asymptomatic case of COVID-19 [ Time Frame: From 14 days after the second dose of study intervention to the end of the study, up to 1 year ]
    Per 1000 person-years of follow-up

  6. Number of participants who experience a first episode of virologically-confirmed {reverse transcription polymerase chain reaction (RT-PCR) positive} mild case of COVID-19 [ Time Frame: From 14 days after the second dose of study intervention to the end of the study, up to 1 year ]
    Per 1000 person-years of follow-up

  7. Number of participants who experience a first episode of virologically-confirmed {reverse transcription polymerase chain reaction (RT-PCR) positive} moderate to severe case of COVID-19 [ Time Frame: From 14 days after the second dose of study intervention to the end of the study, up to 1 year ]
    Per 1000 person-years of follow-up

  8. Number of participants who death due to covid-19 confirmed with (RT-PCR) positive [ Time Frame: From 14 days after the second dose of study intervention to the end of the study, up to 1 year ]
    Per 1000 person-years of follow-up


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Be a male or female 18 years of age or older.
  • For females: Be of non-childbearing potential or willing to use appropriate contraceptive measures for 30 days prior to vaccination through 6 months after completion of the vaccine series.
  • Willingness to provide a signed, printed, and dated informed consent form.
  • Able and willing to participate in all activities in the clinical trial.
  • Participants with HIV, HBV, HCV should have a health record, determined to be stable for 6 months prior to the screening.

Exclusion Criteria:

  • Participants with unstable pre-existing medical conditions over the three months before enrollment (condition that has worsened to require hospitalization or significant changes in therapy).
  • Planned administration/administration of a vaccine not foreseen by the study protocol from within 45 days before the first dose of study vaccine.
  • Previous vaccination with any Covid-19 vaccine.
  • History of COVID-19 disease.
  • History of allergic reactions or anaphylaxis to previous immunizations or allergies to any components of the vaccine.
  • Planning to become pregnant or planning to discontinue contraceptive precautions during the vaccination phase through 6 months after the second immunization.
  • History of bleeding disorders/hemostasis or use of anticoagulants.
  • Currently having cancer or undergoing cancer treatment.
  • Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within 3 months prior to the first vaccine dose (inhaled and topical steroids are allowed).
  • Women who are pregnant or breastfeeding.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04922788


Locations
Layout table for location information
Vietnam
Military Medical Academy
Hanoi, Vietnam
Sponsors and Collaborators
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Investigators
Layout table for investigator information
Study Director: Thuy Nguyen, MD Medical Affairs Department
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Nanogen Pharmaceutical Biotechnology Joint Stock Company
ClinicalTrials.gov Identifier: NCT04922788    
Other Study ID Numbers: NNG27
First Posted: June 11, 2021    Key Record Dates
Last Update Posted: November 4, 2022
Last Verified: November 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
 Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases